Intellia Therapeutics said its Crispr-based treatment for hereditary angioedema met its goals in a Phase 3 trial, marking a ...
Researchers have used modified CRISPR to silence the extra chromosome 21 in Down syndrome cells, showing promising ...
Intellia Therapeutics stock soars on promising Phase 3 results for its hereditary angioedema (HAE) candidate. But is there ...
Money Talks News on MSN
CRISPR cures cholesterol, FDA demands testing
Scientists used CRISPR technology to disable the cholesterol gene in a groundbreaking study, though widespread availability ...
With Phase 3 data in hand, Intellia Therapeutics is seeking approval for its in vivo CRISPR gene editing therapy for ...
Charles Gersbach and his colleagues are pursuing promising CRISPR technologies focused on controlling gene activity rather ...
Intellia Therapeutics has reported the first-ever phase 3 results with an in vivo gene-editing therapy, hereditary angioedema ...
The findings position Intellia to bring to market the first “in vivo” gene editing medicine, though the therapy’s commercial ...
Those questions led us to approach this Nature issue with humility. We try to grapple with them all the time—MIT Technology ...
A research university emphasizes entrepreneurial science—and spawns start-ups in fields as varied as genetic medicine, ...
Qatar has taken a landmark step in precision medicine after Sidra Medicine became the first hospital in the country — and one ...
As cell and gene therapy leaders gathered in Maryland to discuss accelerating clinical trials in children, one “cutting edge” ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results